4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Multiple Sclerosis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1555 ongoing clinical trials involving Multiple Sclerosis
Of the 1555 trials,954 trials are in Phase III
Furthermore, 319 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Multiple Sclerosis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Multiple Sclerosis, a Central Nervous System condition. The largest number of ongoing clinical trials for Multiple Sclerosis is conducted in Europe. Asia-Pacific and North America are among some of the other prominent regions engaged in Multiple Sclerosis-related drug trials.

Novartis AG: The leading ongoing Multiple Sclerosis related clinical trial sponsor

Novartis AG is the top sponsor for Multiple Sclerosis-related ongoing clinical trials.

Biogen Inc, F. Hoffmann-La Roche Ltd, Sanofi and Merck KGaA are among other notable clinical trial sponsors involved in Multiple Sclerosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Multiple Sclerosis

Ocrelizumab (Ocrevus), Dimethyl fumarate (Tecfidera) and Fingolimod hydrochloride (Gilenia, Gilenya, FTY720) are among the key marketed drugs involving Multiple Sclerosis.

Ocrelizumab (Ocrevus) is a humanized monoclonal antibody. It functions via Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20 mechanism of action. Ocrelizumab is formulated as concentrated solution and solution for intravenous route of administration. Ocrelizumab was first approved in 2017 and is marketed globally in the US, UK, France, Germany, Australia and Brazil by several prominent pharma giants including Genentech USA Inc.

Dimethyl fumarate (Tecfidera) is the methyl ester of fumaric acid, acts as an anti-inflammatory and immunomodulatory agent. It functions via Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) Activator mechanism of action. Dimethyl fumarate is formulated as gastro-resistant hard capsules or delayed release capsules for oral route of administration. Dimethyl fumarate was first approved in 2013 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Biogen Inc.